XTL Biopharmaceuticals Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by XTL Biopharmaceuticals Ltd. (Israel) covers the month of May 2026. The report serves to notify shareholders of an upcoming Extraordinary General Meeting of Shareholders scheduled for Monday, June 22, 2026, at 4:00 p.m. Israel time.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The primary update is the scheduling of a corporate governance event.
Guidance, Outlook, and Management Commentary
Management has announced the convening of an Extraordinary General Meeting. The filing includes a Notice and Proxy Statement (Exhibit 99.1) detailing the proposals to be voted upon and voting procedures, as well as a Proxy Card (Exhibit 99.2) for remote voting. No specific business outlook, risk factors, or unusual items are detailed in the body of this report.
Key Facts for Investor Verification
- Meeting Date: June 22, 2026.
- Meeting Time: 4:00 p.m. Israel time.
- Location: Amit Pollack Matalon & Co. Law Offices, Tel Aviv, Israel.
- Shareholders must review Exhibit 99.1 for specific proposals to be voted on.
- Shareholders may vote by proxy using the form in Exhibit 99.2.